IO-202, a first-in-class LILRB4 antagonist antibody, activates dendritic cells and inhibits solid tumor growth in preclinical studies.

Written By Lara Wilson

Costa M. et al. The American Association for Cancer Research (AACR) Annual Meeting 2021, Virtual. April 10-15, 2021

Lara Wilson
Previous

Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells
Next

Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer